WO2010069951A1 - Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins - Google Patents

Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins Download PDF

Info

Publication number
WO2010069951A1
WO2010069951A1 PCT/EP2009/067175 EP2009067175W WO2010069951A1 WO 2010069951 A1 WO2010069951 A1 WO 2010069951A1 EP 2009067175 W EP2009067175 W EP 2009067175W WO 2010069951 A1 WO2010069951 A1 WO 2010069951A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acids
omega
natural
semi
polyenoic fatty
Prior art date
Application number
PCT/EP2009/067175
Other languages
French (fr)
Inventor
Roberto Valducci
Tiziano Alighieri
Serozh Avanessian
Original Assignee
Valpharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma S.A. filed Critical Valpharma S.A.
Publication of WO2010069951A1 publication Critical patent/WO2010069951A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to the field of formulations containing omega polyenoic fatty acids in combination with natural or semi-synthetic statins.
  • Omega polyenoic fatty acids are long chain polyunsaturated fatty acids with between
  • omega-3-polyenoic fatty acids in which the first unsaturated bond is between the third and the fourth carbon atom, from the terminal methyl group
  • omega-6-polyenoic fatty acids in which the first unsaturated bond is between the sixth and the seventh carbon atom
  • omega-3-polyenoic fatty acids in which fish oil is rich, the most widespread are eicosapentaenoic acid, generally indicated with the acronym EPA, and docosahexaenoic acid, indicated with the acronym DHA.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • omega polyenoic fatty acids compete with arachidonic acid for binding to the enzymes cyclooxygenase and lipoxygenase, causing a reduction in blood triglyceride levels; moreover, they have an anti-aggregation and antithrombotic action due to their effect of reducing thromboxane A2 synthesis; they promote vasodilation and increase bleeding time .
  • omega polyenoic fatty acids are indicated in the prevention of recurrences after angioplasty surgery and for reducing angina attacks, as well as for treating hypertriglyceridemia, when combined with modified dietary regimens or also when the response to diets and other non-pharmacological measures alone has proved inadequate.
  • omega polyenoic fatty acids fish oil esters
  • statins such as simvastatin and other statins.
  • Consumption of omega polyenoic fatty acids can allow cholesterol lowering drugs, such as statins (which can be of synthetic or natural origin) to function more effectively.
  • the polyenoic fatty acids according to the invention are preferably chosen in the group consisting of omega-3-polyenoic fatty acids, omega-6-polyenoic fatty acids, and their mixtures, more preferably mixtures of omega-3-polyenoic fatty acids.
  • Particularly preferred according to the invention are mixtures of omega-3- polyenoic fatty acids containing EPA and DHA in quantities between 20 - 98% by weight calculated on the total weight of the mixture, and preferably in quantities equal to at least 60% by weight.
  • the ratio by weight of EPA and DHA is, for example, between 0.05 and 2.5, and preferably between 0.9 and 1.5.
  • the term natural or semi-synthetic statins is intended as fermented red rice, garlic and artichoke extracts and polyphenols from vitis vinifera.
  • fermented red rice having a content of Lovastatin and Monacolin K higher than 1.5% by weight.
  • the fermented red rice is obtained from fermentation of the common cooking rice ⁇ Oryza sativa), by means of a particular yeast, called Monascus purpureus or red yeast .
  • This rice which owes its name to its characteristic colour, is a conventional component of Chinese phytotherapy but is also widely known in the Western world for its valuable hypolipidemic effects.
  • monacolin K stands out, as it reflects the chemical structure and pharmacological action of lovastatin (a drug belonging to the statin category).
  • the monacolin K of red rice is capable of inhibiting HMG-CoA reductase, which represents a key enzyme in the biosynthesis of cholesterol.
  • HMG-CoA reductase represents a key enzyme in the biosynthesis of cholesterol.
  • fermented red rice is more effective with respect to the administration of equivalent dosages of lovastatin, proving that its properties reflect a combination of actions that cannot be attributed solely to monacolin K. Also for this reason, besides its well-documented hypolipidemizing activity, fermented red rice seems to reduce cardiovascular risk due to antiatheroschlerotic activities of other type (antinflammatory, vasodilating and reductive effect on lipoprotein A levels). Controlled fermentation in the laboratory can also slightly vary the composition of Monascus purpureus and allow the selection of strains rich in Monacolin K or other substances having particular pharmacological actions.
  • Natural or semi-synthetic statins - preferably fermented red rice - are present in the formulation of the invention in the quantities permitted for nutraceutical formulations, in particular up to 3 mg.
  • the two active principles - fatty acids on the one hand and one or more natural or semi-synthetic statins on the other - are kept isolated from each other inside a same dosage unit.
  • the active principle present in the higher dosage i.e. the fatty acid
  • the second active principle is uniformly distributed on the capsule.
  • Vitamin E Ascorbic acid
  • these components act as stabilizers for the formulation of the invention.
  • the present formulations typically contain, inside the capsule, from 100 to 1 ,500 mg of fatty acids, preferably around 1 ,000 mg.
  • Natural or semi-synthetic statins are applied to the capsule with one or more film- coating agents and possibly one or more inert substances, using appropriate solvents.
  • One or more further film coatings without said active principles and comprising one or more appropriate film-coating agents, possibly in admixture with at least an inert subtance, can be applied to the filmed coating containing the second active principle.
  • film-coating agents chosen among hydroxy propyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol / polyethylene glycol copolymers, and their mixtures are preferred; while the possible inert substance is chosen among lactose monohydrate, polyalcohols and other substances permitted for products intended for particular nutritional uses.
  • EXAMPLE 1 EXAMPLE 1
  • 10,600 soft gelatin capsules were prepared, containing 500 mg of omega-3-polyenoic fatty acids per capsule with a minimum EPA-DHA content of 30%. These capsules were placed in a coating pan equipped with automatic spray, product and air inlet temperature control system and nebulized with a suspension having the following composition, in order to obtain a fermented red rice content of
  • statins Fermented red rice 1.5% 2,375 g
  • Nebulization pressure 0.5 bar
  • the capsules obtained were film-coated with a solution having the following composition: Hydroxy propyl methylcellulose 109 g
  • the film-coating process was performed setting the following operating parameter on the equipment:
  • Nebulization pressure 1 bar Pump speed: 15-25 rpm
  • the capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and
  • Example 1 In the same operating conditions described in Example 1 , a suspension, having the following composition, was nebulized onto 10,600 soft gelatin capsules containing approximately 500 mg of the mixture of fatty acids of Example 1 :
  • the capsules obtained were film-coated in the same operating conditions described in Example 1 with a coating solution having the following composition: Hydroxy propyl methylcellulose 109 g
  • the capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and 75% relative humidity, and were found to have the same stability as the capsules of
  • Example 1 with regard to the fermented red rice content.
  • 10,600 soft gelatin capsules were prepared, containing 1000 mg of omega-3- polyenoic fatty acids per capsule with a minimum EPA-DHA content of 70%.
  • Nebulization pressure 0.5 bar Pump speed: 15-25 rpm
  • the capsules obtained were film-coated with a coating solution having the following composition:
  • the film-coating process was performed by setting the following operating parameters on the equipment:
  • the capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and 75% relative humidity, and were found to have the same stability as the capsules of
  • Example 2 In the same operating conditions described in Example 1 , 2,800 soft gelatin capsules, containing approximately 500 mg of mixture of fatty acids, were nebulized with a suspension having the following composition: Fermented red rice 1.5% 630 g
  • the capsules obtained were film-coated in the same operating conditions described in Example 1 with a coating solution having the following composition:

Abstract

There are described formulations for nutritional use for the oral administration of a single dose containing omega polyenoic fatty acids, in combination with natural or semi-synthetic statins and possible other nutrients; also described is the process for preparation of stable formulations.

Description

ORAL FORMULATIONS COMPRISING OMEGA POLYENOIC FATTY ACIDS IN COMBINATION WITH NATURAL OR SEMI -SYNTHETI C STATINS
FIELD OF THE INVENTION The present invention relates to the field of formulations containing omega polyenoic fatty acids in combination with natural or semi-synthetic statins.
STATE OF THE ART
Omega polyenoic fatty acids are long chain polyunsaturated fatty acids with between
18 and 22 carbon atoms; among these, omega-3-polyenoic fatty acids, in which the first unsaturated bond is between the third and the fourth carbon atom, from the terminal methyl group, and omega-6-polyenoic fatty acids, in which the first unsaturated bond is between the sixth and the seventh carbon atom, are essential.
Among the omega-3-polyenoic fatty acids, in which fish oil is rich, the most widespread are eicosapentaenoic acid, generally indicated with the acronym EPA, and docosahexaenoic acid, indicated with the acronym DHA. Another important omega-3-polyenoic fatty acid, not of fish but of vegetable origin, is alpha-linolenic acid, indicated with the acronym ALA.
It has been widely proven that omega polyenoic fatty acids compete with arachidonic acid for binding to the enzymes cyclooxygenase and lipoxygenase, causing a reduction in blood triglyceride levels; moreover, they have an anti-aggregation and antithrombotic action due to their effect of reducing thromboxane A2 synthesis; they promote vasodilation and increase bleeding time .
Due to these valuable biological effects, omega polyenoic fatty acids are indicated in the prevention of recurrences after angioplasty surgery and for reducing angina attacks, as well as for treating hypertriglyceridemia, when combined with modified dietary regimens or also when the response to diets and other non-pharmacological measures alone has proved inadequate.
In the vast majority of cases food sources of omega polyenoic fatty acids are not in fact sufficient to achieve an adequate therapeutic or preventive response and to obtain an adequate source of daily administration these acids must be consumed in the form of pharmaceutical formulations or products intended for special nutritional uses, such as the one forming the subject matter of the present invention. In the pharmaceutical field, omega polyenoic fatty acids (fish oil esters) are in general combined with synthetic statins, such as simvastatin and other statins. Consumption of omega polyenoic fatty acids can allow cholesterol lowering drugs, such as statins (which can be of synthetic or natural origin) to function more effectively. The patent application PCT/EP2007/056344 by the same applicant describes formulations for the oral administration of omega polyenoic fatty acids in combination with active principles incompatible therewith, including synthetic statins (for example simvastatin). However, it must be considered that synthetic statins are considered a true drug, while in many cases the use of products of natural origin is more indicated, as these can also be used in the production of dietary supplements.
To date no formulations are known that contain the two components (omega polyenoic fatty acids and natural or semi-synthetic statins) and to obtain the effective benefits of their combination, it is necessary to administer several formulations, each containing only one of the components, due to technical prejudices and difficulties in the preparation of a single dose containing an oily liquid component and a powder component incompatible therewith. The advantages of instead being able to provide a single formulation for the simultaneous oral administration of omega polyenoic fatty acids and natural statins, especially in terms of patient compliance, are evident and the need was therefore felt to provide a formulation of this type. SUMMARY OF THE INVENTION
There are described pharmaceutical formulations for oral administration comprising omega polyenoic fatty acids in combination with natural or semi-synthetic statins, their preparation methods and their use. DETAILED DESCRIPTION OF THE INVENTION
With the present invention, these problems are overcome through a non- pharmaceutical formulation for the oral administration of omega polyenoic fatty acids in combination with natural or semi-synthetic statins. The polyenoic fatty acids according to the invention are preferably chosen in the group consisting of omega-3-polyenoic fatty acids, omega-6-polyenoic fatty acids, and their mixtures, more preferably mixtures of omega-3-polyenoic fatty acids. Particularly preferred according to the invention are mixtures of omega-3- polyenoic fatty acids containing EPA and DHA in quantities between 20 - 98% by weight calculated on the total weight of the mixture, and preferably in quantities equal to at least 60% by weight. In these mixtures the ratio by weight of EPA and DHA is, for example, between 0.05 and 2.5, and preferably between 0.9 and 1.5.
According to the invention, the term natural or semi-synthetic statins is intended as fermented red rice, garlic and artichoke extracts and polyphenols from vitis vinifera. Particularly preferred is fermented red rice having a content of Lovastatin and Monacolin K higher than 1.5% by weight. The fermented red rice is obtained from fermentation of the common cooking rice {Oryza sativa), by means of a particular yeast, called Monascus purpureus or red yeast . This rice, which owes its name to its characteristic colour, is a conventional component of Chinese phytotherapy but is also widely known in the Western world for its valuable hypolipidemic effects. The enormous scientific and economic interest surrounding red rice is linked to the presence of Monascus purpureus; during its fermenting activity, this yeast is in fact enriched by a group of substances, called monacolins, which have been scientifically associated with marked hypocholesterolemizing activity. Among these, monacolin K stands out, as it reflects the chemical structure and pharmacological action of lovastatin (a drug belonging to the statin category). Similarly to these pharmaceutical products, the monacolin K of red rice is capable of inhibiting HMG-CoA reductase, which represents a key enzyme in the biosynthesis of cholesterol. As its plasma levels depend above all on this biosynthetic pathway (and only to a lesser extent on diet): integration with fermented red rice has proved effective in normalizing total cholesterol, LDL cholesterol and triglyceride levels.
In this sense, fermented red rice is more effective with respect to the administration of equivalent dosages of lovastatin, proving that its properties reflect a combination of actions that cannot be attributed solely to monacolin K. Also for this reason, besides its well-documented hypolipidemizing activity, fermented red rice seems to reduce cardiovascular risk due to antiatheroschlerotic activities of other type (antinflammatory, vasodilating and reductive effect on lipoprotein A levels). Controlled fermentation in the laboratory can also slightly vary the composition of Monascus purpureus and allow the selection of strains rich in Monacolin K or other substances having particular pharmacological actions.
Natural or semi-synthetic statins - preferably fermented red rice - are present in the formulation of the invention in the quantities permitted for nutraceutical formulations, in particular up to 3 mg.
Preferably, according to the invention, the two active principles - fatty acids on the one hand and one or more natural or semi-synthetic statins on the other - are kept isolated from each other inside a same dosage unit. Preferably, the active principle present in the higher dosage, i.e. the fatty acid, is encapsulated, in a soft or hard gelatin capsule, while the second active principle, possibly in combination with one or more other active principles, is uniformly distributed on the capsule.
Among the active principles as defined above we can, for example choose: Vitamin E, Ascorbic acid and their mixtures. Besides supplying a vitamin, these components act as stabilizers for the formulation of the invention.
According to the invention, the present formulations typically contain, inside the capsule, from 100 to 1 ,500 mg of fatty acids, preferably around 1 ,000 mg. Natural or semi-synthetic statins are applied to the capsule with one or more film- coating agents and possibly one or more inert substances, using appropriate solvents.
One or more further film coatings without said active principles and comprising one or more appropriate film-coating agents, possibly in admixture with at least an inert subtance, can be applied to the filmed coating containing the second active principle. Among the film-coating agents that can be used according to the invention, film-coating agents chosen among hydroxy propyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol / polyethylene glycol copolymers, and their mixtures are preferred; while the possible inert substance is chosen among lactose monohydrate, polyalcohols and other substances permitted for products intended for particular nutritional uses. The following examples are given by way of non-limiting illustration of the invention. EXAMPLE 1
10,600 soft gelatin capsules were prepared, containing 500 mg of omega-3-polyenoic fatty acids per capsule with a minimum EPA-DHA content of 30%. These capsules were placed in a coating pan equipped with automatic spray, product and air inlet temperature control system and nebulized with a suspension having the following composition, in order to obtain a fermented red rice content of
200 mg per capsule equal to 3 mg of statins: Fermented red rice 1.5% 2,375 g
Ascorbic acid 382 g
Vitamin E 191 g
Polyvinylpyrrolidone 687 g
Ethano 2,748 g Acetone 6,106 g
Processing was performed by setting the following operating parameters on the equipment:
Coating pan revolutions: 8 rpm
Inlet air temperature: 52 °C Nozzle: 1 mm hole
Nebulization pressure: 0.5 bar
Pump speed: 15-25 rpm
The capsules obtained were film-coated with a solution having the following composition: Hydroxy propyl methylcellulose 109 g
Acetone 930 g
Ethanol 930 g
Water 21 O g
The film-coating process was performed setting the following operating parameter on the equipment:
Coating pan revolutions: 8 rpm
Inlet air temperature: 45 °C
Nozzle: 1 mm hole
Nebulization pressure: 1 bar Pump speed: 15-25 rpm
At the end of the film-coating process and subsequent drying the capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and
75% relative humidity, obtaining the following results in relation to fermented red rice content:
25 °C 60% RH 40 °C 75% RH Time (0) 198.9 mg/capsule 198.9 mg/capsule
3 months: 206 mg/capsule 196.3 mg/capsule
EXAMPLE 2
In the same operating conditions described in Example 1 , a suspension, having the following composition, was nebulized onto 10,600 soft gelatin capsules containing approximately 500 mg of the mixture of fatty acids of Example 1 :
Fermented red rice 3% 1 ,18O g
Lactose monohydrate 1 ,18O g
Ascorbic acid 382 g
Vitamin E 191 g Polyvinylpyrrolidone 687 g
Ethanol 2,748 g
Acetone 6,106 g
The capsules obtained were film-coated in the same operating conditions described in Example 1 with a coating solution having the following composition: Hydroxy propyl methylcellulose 109 g
Acetone 930 g
Ethanol 930 g
Water 21 O g
The capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and 75% relative humidity, and were found to have the same stability as the capsules of
Example 1 with regard to the fermented red rice content.
EXAMPLE 3
10,600 soft gelatin capsules were prepared, containing 1000 mg of omega-3- polyenoic fatty acids per capsule with a minimum EPA-DHA content of 70%.
These capsules were placed in a coating pan equipped with automatic spray, product and air inlet temperature control system and nebulized with a suspension having the following composition in order to obtain a fermented red rice content of 200 mg per capsule equivalent to 3 mg of statins:
Fermented red rice 1.5% 2,375 g
Ascorbic acid 382 g Vitamin E 191 g
Polyvinylpyrrolidone 687 g
Ethanol 2,748 g
Acetone 6,106 g
Processing was performed by setting the following operating parameters on the equipment:
Coating pan revolutions: 8 rpm
Inlet air temperature: 52 °C
Nozzle: 1 mm hole
Nebulization pressure: 0.5 bar Pump speed: 15-25 rpm
The capsules obtained were film-coated with a coating solution having the following composition:
Hydroxy propyl methylcellulose 109 g
Acetone 930 g Ethanol 930 g
Water 21 O g
The film-coating process was performed by setting the following operating parameters on the equipment:
Coating pan revolutions: 8 rpm Inlet air temperature: 45 °C
Nozzle: 1 mm hole
Nebulization pressure: 1 bar
Pump speed: 15-25 rpm
The capsules were analyzed and packed in polythene bottles to perform a stability study at 25 °C and 60% relative humidity and at 40 °C and 75% relative humidity, and were found to have the same stability as the capsules of
Example 1 with regard to the fermented red rice content. EXAMPLE 4
In the same operating conditions described in Example 1 , 2,800 soft gelatin capsules, containing approximately 500 mg of mixture of fatty acids, were nebulized with a suspension having the following composition: Fermented red rice 1.5% 630 g
Polyvinylpyrrolidone 189 g
Ethanol 2,220 g
Water 100 g
The capsules obtained were film-coated in the same operating conditions described in Example 1 with a coating solution having the following composition:
Hydroxy propyl methylcellulose 50 g
Acetone 425 g
Ethanol 425 g
Water 100 g The capsules were analyzed obtaining a fermented red rice content equal to 205 mg/capsule.
EXAMPLE 5
In the same operating conditions described in Example 4, 2,800 soft gelatin capsules, containing approximately 500 mg of the mixture of fatty acids, were nebulized with a suspension having the following composition:
Fermented red rice 1.5% 630 g
Polyvinyl alcohol / polyethylene glycol copolymer 280 g
Ethanol 1 ,260 g
Water 1 ,260 g The capsules obtained were film-coated in the same operating conditions and with the same coating solution as Example 4, obtaining at the end of the analytical tests a fermented red rice content equal to 200 mg/capsule.

Claims

1. Nutritional formulations for the oral administration of omega polyenoic fatty acids in combination with natural or semi-synthetic statins.
2. Nutritional formulations according to Claim 1 wherein said polyenoic fatty acids are chosen in the group consisting of: omega-3-polyenoic fatty acids, omega-6- polyenoic fatty acids, and their mixtures, preferably mixtures of omega-3- polyenoic fatty acids.
3. Formulations according to Claim 2 wherein said mixtures of omega-3-polyenoic fatty acids comprise EPA and DHA in quantities between 20 - 98% by weight calculated on the total weight of the mixture.
4. Formulations according to claims 1 - 3 wherein said natural or semi-synthetic statins are chosen in the group consisting of: fermented red rice, garlic and artichoke extracts and polyphenols from vitis vinifera..
5. Formulations according to Claim 4 wherein said statins are fermented red rice having a content of Lovastatin and Monacolin K higher than 1.5% by weight.
6. Formulations according to claims 4 and 5 wherein said natural or semi-synthetic statins are present in the quantities permitted for nutraceutical formulations, in particular up to 3 mg.
7. Formulations according to claims 1 - 6 wherein said omega polyenoic fatty acids and said natural or semi-synthetic statins are kept isolated from each other in a single dosage unit.
8. Formulations according to claim 7 wherein the fatty acid is encapsulated while the second active principle, possibly in combination with one or more other active principles, is uniformly distributed on said capsule.
9. Formulations according to claim 7 wherein said other active principles are chosen among: Vitamin E, ascorbic acid and their mixtures.
10. Process for the preparation of formulations according to claims 1 -9 wherein natural or semi-synthetic statins are applied to the capsule with one or more film- coating agents and possibly one or more inert substances, using appropriate solvents, and one or more further film coatings, without said active principles but containing one or more appropriate film-coating agents, possibly in admixture with at least an inert substance, are possibly applied to the capsule thus obtained.
1. Process according to claim 10 wherein said film-coating agents are chosen among hydroxy propyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol / polyethylene glycol copolymers, and their mixtures; while the possible inert substance is chosen among lactose monohydrate, polyalcohols and other substances used for the preparation of nutraceuticals.
PCT/EP2009/067175 2008-12-15 2009-12-15 Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins WO2010069951A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000243A ITFI20080243A1 (en) 2008-12-15 2008-12-15 FORMULATIONS FOR ORAL ADMINISTRATION OF OMEGA POLIENOIC FATTY ACIDS IN COMBINATION WITH NATURAL OR SEMI-SYNTHETIC STATINES.
ITFI2008A000243 2008-12-15

Publications (1)

Publication Number Publication Date
WO2010069951A1 true WO2010069951A1 (en) 2010-06-24

Family

ID=40600075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/067175 WO2010069951A1 (en) 2008-12-15 2009-12-15 Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins

Country Status (2)

Country Link
IT (1) ITFI20080243A1 (en)
WO (1) WO2010069951A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2506848A1 (en) * 2009-12-03 2012-10-10 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
US20140010872A1 (en) * 2011-03-23 2014-01-09 Hanmi Pharm. Co., Ltd. Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor
WO2014153567A3 (en) * 2013-03-05 2015-06-04 Innovative Environmental Technologies, Inc. Inhibition of methane production during anaerobic reductive dechlorination
EP2853263A4 (en) * 2012-05-22 2016-01-13 Kuhnil Pharm Co Ltd Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043659A2 (en) * 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
WO2002100394A1 (en) * 2001-06-12 2002-12-19 Galephar M/F Oral pharmaceutical composition containing a statin derivative
WO2004058281A1 (en) * 2002-12-24 2004-07-15 Nutrinova Nutrition Specialties & Food Ingedients Gmbh Cholesterol-reducing agent containing an n-3 fatty acid
WO2006013602A1 (en) * 2004-08-03 2006-02-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition containing statins and omega-3 fatty acids
WO2006016357A1 (en) * 2004-08-09 2006-02-16 Enzymotec Ltd. Food products for diabetics
WO2006021293A1 (en) * 2004-08-23 2006-03-02 Unilever N.V. Composition comprising statin
WO2006096806A2 (en) * 2005-03-08 2006-09-14 Reliant Pharmaceutiacals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
WO2006132879A2 (en) * 2005-06-03 2006-12-14 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
WO2007019373A2 (en) * 2005-08-04 2007-02-15 Transform Pharmaceuticals, Inc. Novel formulations comprising fenofibrate and a statin, and related methods of treatment
EP1803440A1 (en) * 2004-10-19 2007-07-04 GP Pharm S.A. Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa)
WO2007103557A2 (en) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
CN101091708A (en) * 2006-06-22 2007-12-26 沈阳东宇药业有限公司 Composition for reducing blood fat, and preparation method
WO2008000731A2 (en) * 2006-06-26 2008-01-03 Valpharma S.A. Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
WO2008146016A2 (en) * 2007-05-31 2008-12-04 Omegatri A/S Cyclodextrins for administering fatty acids in tablets
US20080299187A1 (en) * 2007-06-01 2008-12-04 Joar Opheim Substances for Reducing Occurence of Major Cardiac Events in Humans
WO2009032699A1 (en) * 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
WO2009059717A2 (en) * 2007-11-08 2009-05-14 Iervant Zarmanian Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use
WO2009087938A1 (en) * 2008-01-10 2009-07-16 Takeda Pharmaceutical Company Limited Capsule formulation

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043659A2 (en) * 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
WO2002100394A1 (en) * 2001-06-12 2002-12-19 Galephar M/F Oral pharmaceutical composition containing a statin derivative
WO2004058281A1 (en) * 2002-12-24 2004-07-15 Nutrinova Nutrition Specialties & Food Ingedients Gmbh Cholesterol-reducing agent containing an n-3 fatty acid
WO2006013602A1 (en) * 2004-08-03 2006-02-09 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition containing statins and omega-3 fatty acids
WO2006016357A1 (en) * 2004-08-09 2006-02-16 Enzymotec Ltd. Food products for diabetics
WO2006021293A1 (en) * 2004-08-23 2006-03-02 Unilever N.V. Composition comprising statin
EP1803440A1 (en) * 2004-10-19 2007-07-04 GP Pharm S.A. Pharmaceutical formulation comprising microcapusles of statins suspended in alkyl esters of polyunsaturated fatty acids (pufa)
WO2006096806A2 (en) * 2005-03-08 2006-09-14 Reliant Pharmaceutiacals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
WO2006132879A2 (en) * 2005-06-03 2006-12-14 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
WO2007019373A2 (en) * 2005-08-04 2007-02-15 Transform Pharmaceuticals, Inc. Novel formulations comprising fenofibrate and a statin, and related methods of treatment
WO2007103557A2 (en) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
CN101091708A (en) * 2006-06-22 2007-12-26 沈阳东宇药业有限公司 Composition for reducing blood fat, and preparation method
WO2008000731A2 (en) * 2006-06-26 2008-01-03 Valpharma S.A. Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
WO2008146016A2 (en) * 2007-05-31 2008-12-04 Omegatri A/S Cyclodextrins for administering fatty acids in tablets
US20080299187A1 (en) * 2007-06-01 2008-12-04 Joar Opheim Substances for Reducing Occurence of Major Cardiac Events in Humans
WO2009032699A1 (en) * 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
WO2009059717A2 (en) * 2007-11-08 2009-05-14 Iervant Zarmanian Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use
WO2009087938A1 (en) * 2008-01-10 2009-07-16 Takeda Pharmaceutical Company Limited Capsule formulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Statin", WIKIPEDIA, THE FREE ENCYCLOPEDIA, 4 May 2009 (2009-05-04), XP002527461, Retrieved from the Internet <URL:http://en.wikipedia.org/wiki/Statin> [retrieved on 20090512] *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2008, XP002527431, retrieved from STN Database accession no. 2008:1630 *
DATABASE WPI Week 200949, Derwent World Patents Index; AN 2009-L52520, XP002574670 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596121B2 (en) 2007-06-01 2020-03-24 Nordic Naturals, Inc. Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
US11406602B2 (en) 2007-06-01 2022-08-09 Nordic Naturals, Inc. Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
EP2506848A1 (en) * 2009-12-03 2012-10-10 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
EP2506848A4 (en) * 2009-12-03 2013-07-31 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
AU2010326054B2 (en) * 2009-12-03 2015-02-05 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice and omega-3 polyunsaturated fatty acid or derivative thereof
US20140010872A1 (en) * 2011-03-23 2014-01-09 Hanmi Pharm. Co., Ltd. Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
EP2853263A4 (en) * 2012-05-22 2016-01-13 Kuhnil Pharm Co Ltd Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
US9320718B2 (en) 2012-05-22 2016-04-26 Kuhnil Pharm. Co., Ltd. Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug
WO2014153567A3 (en) * 2013-03-05 2015-06-04 Innovative Environmental Technologies, Inc. Inhibition of methane production during anaerobic reductive dechlorination

Also Published As

Publication number Publication date
ITFI20080243A1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
Scicchitano et al. Nutraceuticals and dyslipidaemia: beyond the common therapeutics
Trox et al. Bioactive compounds in cashew nut (Anacardium occidentale L.) kernels: effect of different shelling methods
Maeda et al. Seaweed carotenoid, fucoxanthin, as a multi-functional nutrient.
Kamal-Eldin et al. Sesame seed lignans: potent physiological modulators and possible ingredients in functional foods & nutraceuticals
CA2640414C (en) Combinations of botanical extracts for promoting cardiovascular health
US20120219619A1 (en) Substances for reducing occurrence of major cardiac events in humans
Yang et al. Chemical profile and antioxidant activity of the oil from peony seeds (Paeonia suffruticosa Andr.)
US8507466B2 (en) Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
KR101791278B1 (en) Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
KR20220041871A (en) Formulations comprising an omega-3 fatty acid salt and an extract of gum resin from Boswellia spp.
WO2010069951A1 (en) Oral formulations comprising omega polyenoic fatty acids in combination with natural or semi -synthetic statins
WO2008000731A2 (en) Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
Zou et al. Silkworm pupae oil exerts hypercholesterolemic and antioxidant effects in high‐cholesterol diet‐fed rats
Mezzomo et al. Evidence of anti-obesity and mixed hypolipidemic effects of extracts from pink shrimp (Penaeus brasiliensis and Penaeus paulensis) processing residue
NZ541887A (en) Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides
JP2010100545A (en) Activation enhancer of nuclear receptor and/or transcription factor
Sut et al. Food-derived nutraceuticals for hypercholesterolemia management, mode of action and active ingredients.
da Mata et al. Different biological activities (antimicrobial, antitumoral, and antioxidant activities) of grape seed oil
WO2019026067A1 (en) Extracts of nannochloropsis microalgae and their uses
Tsoupras et al. Bioactive Metabolites from Fungi with Anti-Inflammatory and Antithrombotic Properties: Current Status and Future Perspectives for Drug Development
Manosroi et al. In vitro immunostimulating activity of the dried sap from fermented thai rice on human and murine neutrophils
Sari et al. Fat-Rich Food Review on Obesity Control through Induction Enzyme Inhibitors
CA2676583C (en) Composition comprising red yeast rice and an omega-3 polyunsaturated fatty acid
Zafar et al. Herbal Seeds for Lowering Low Density Lipoprotein Cholesterol and To Increase High Density Lipoprotein Cholesterol
Houston Nutrition and Nutritional Supplements in the Management of Dyslipidemia—Part 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09801432

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09801432

Country of ref document: EP

Kind code of ref document: A1